Influenza A virus resistance to 4'-fluorouridine coincides with viral attenuation in vitro and in vivo .
Carolin M LieberHae-Ji KangMegha AggarwalNicole A LiebermanElizabeth B SobolikJeong-Joong YoonMichael G NatchusRobert M CoxAlexander L GreningerRichard K PlemperPublished in: bioRxiv : the preprint server for biology (2023)
Reduced sensitivity to FDA-approved influenza drugs is a major obstacle to effective antiviral therapy. We have previously demonstrated oral efficacy of a novel clinical candidate drug, 4'-FlU, against seasonal, pandemic, and highly pathogenic avian influenza viruses. In this study, we have determined possible routes of influenza virus escape from 4'-FlU and addressed whether resistance imposes a viral fitness penalty, affecting pathogenicity or ability to transmit. We identified three distinct clusters of mutations that lead to moderately reduced viral sensitivity to the drug. Testing of resistant variants against two chemically unrelated nucleoside analog inhibitors of influenza virus, conditionally approved favipiravir and the broad-spectrum SARS-CoV-2 drug molnupiravir, revealed cross-resistance of one cluster with favipiravir, whereas no viral escape from molnupiravir was noted. We found that the resistant variants are severely attenuated in mice, impaired in their ability to invade the lower respiratory tract and cause viral pneumonia in ferrets, and transmission-defective or compromised. We could fully mitigate lethal infection of mice with the resistant variants with standard or 5-fold elevated oral dose of 4'-FlU. These results demonstrate that partial viral escape from 4'-FlU is feasible in principle, but escape mutation clusters are unlikely to reach clinical significance or persist in circulating influenza virus strains.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- respiratory tract
- copy number
- type diabetes
- stem cells
- escherichia coli
- emergency department
- high fat diet induced
- metabolic syndrome
- physical activity
- body composition
- intensive care unit
- gene expression
- insulin resistance
- coronavirus disease
- mesenchymal stem cells
- dna methylation
- cell therapy
- adverse drug
- cystic fibrosis